Niraparib plus Bevacizumab as First Line Maintenance
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Niraparib plus Bevacizumab as First Line Maintenance

Sponsor: TESARO, Inc.

A phase 2 study of niraparib, a PARP inhibitor, combined with bevacizumab as maintenance for patients with ovarian, Fallopian, or primary peritoneal cancers following first line treatment with a platinum-based chemotherapy regimen containing bevacizumab.